Document is current
Any future updates will be listed below
-
Authors
Jodl, Stefan J. https://orcid.org/0009-0005-4268-3588
Worm, Margitta
Friedrichs, Frauke https://orcid.org/0009-0002-7005-8964
Heinzel-Pleines, Ulrike https://orcid.org/0009-0005-7183-1973
Wagenfeld, Andrea https://orcid.org/0000-0001-9648-4318
Feldmüller, Maximilian https://orcid.org/0000-0002-4316-2398
Klein, Stefan
Zhang, Ruiping https://orcid.org/0000-0003-4095-7600
Shakery, Kaweh https://orcid.org/0000-0003-2350-7624
Holzmann, Ruth D.
Rohde, Beate
Perera, Vidya
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05656911 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and Safety of Zabedosertib, an Interleukin-1 Receptor-Associated Kinase 4 Inhibitor, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II Randomized Study
https://doi.org/10.1007/s13555-025-01505-z
-
Funding
Funding for this research was provided by:
Bayer
- License Information
-
More Information
Article History
Received: 25 April 2025
Accepted: 21 July 2025
First Online: 4 September 2025
Declarations
:
: Stefan J Jodl, Frauke Friedrichs, Ulrike Heinzel-Pleines, Andrea Wagenfeld, Maximilian Feldmüller, Stefan Klein, Ruiping Zhang, Kaweh Shakery, Ruth D Holzmann, Beate Rohde, and Vidya Perera are employees of Bayer AG. Stefan J Jodl, Kaweh Shakery, Maximilian Feldmüller, and Vidya Perera are shareholders of Bayer AG. Margitta Worm has received investigator and consultancy fees from Bayer AG.
: The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. All participating study sites have received approval from an institutional review board (Germany: AM-2022-017, Ethik-Kommission bei der Landesärztekammer Baden-Württemberg, Liebknechtstraße 33, 70565 Stuttgart, Germany). All subjects provided informed consent to participate in the study.
